Methotrexate

Showing study: Methotrexate for the Treatment of Crohn's Disease (Feagan et al.)

Benefits

Risk

Overtime:
SHOW:
grid-1
grid-1

Benefit

Harm

Study overview

  • Figure shows absolute benefit/risk. This is calculated by assessing benefit/risk of study drug against placebo, except where stated
  • Double-blind, placebo-controlled multicenter study of weekly injections of methotrexate in patients who had chronically active Crohn's disease despite a minimum of three months of prednisone therapy
  • Patients were randomly assigned to treatment with intramuscular methotrexate (25 mg once weekly) or placebo for 16 weeks
  • Patients also received prednisone (20 mg once a day), which was tapered over a period of 10 weeks unless their condition worsened
  • Primary outcome measure was clinical remission at the end of the 16-week trial
  • Remission was defined by the discontinuation of prednisone and a score of <150 points on the Crohn's Disease Activity Index

Terms and conditions

By using this site you acknowledge that the content of this website is based on a review process of the ECCO Consensus Guidelines and primarily aims at facilitating their visualization.

Any treatment decisions are a matter for individual clinicians and may not be based primarily on the e-Guide content.

The European Crohn's and Colitis Organisation and/or any of its staff members and/or any website contributor may not be held liable for any information published in good faith on this website.

You agree that the use of this website is at your own risk and hereby waive any and all potential claims against European Crohn's and Colitis Organisation, and/or any of its staff members and/or any of the website contributors.